NovaBay's impetigo drug aces Phase II trial

NovaBay Pharmaceuticals' lead drug candidate NVC-422 was shown to be safe and effective in a mid-stage trial. The drug was tested at three doses against the contagious skin infection impetigo, including infections caused bymethicillin-resistant Staphylococcus aureus (MRSA). Results showed a trend towards a dose response. NovaBay says in a statement that it plans to "aggressively" pursue development of NVC-422 as a first-line treatment for a range of topical infections. Release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.